|
| Status |
Public on Mar 07, 2022 |
| Title |
Next-generation mRNA sequencing of MKL-1 Merkel cell carcinoma cells treated with EPZ011989 |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
The overarching goal of this study was to characterize mechanisms of sensitivity to EZH2 inhibitors in Merkel cell carcinoma cell lines. To that end, early and late transcriptional changes were profiled in MKL-1 cells treated with the EZH2 inhibitor EPZ011989 for 6 or 12 days.
|
| |
|
| Overall design |
MKL-1 cells were treated in triplicate with 3 µM EPZ011989 or vehicle (1% ethanol) for 6 or 12 days with refreshment every 3 days. 12 samples are analyzed.
|
| |
|
| Contributor(s) |
Gartin AK |
| Citation(s) |
35331717 |
| |
| Submission date |
Nov 01, 2021 |
| Last update date |
Jun 13, 2022 |
| Contact name |
Ashley K. Gartin |
| Organization name |
Dana-Farber Cancer Institute
|
| Department |
Medical Oncology
|
| Lab |
DeCaprio Lab
|
| Street address |
450 Brookline Ave. Mayer 444
|
| City |
Boston |
| State/province |
MA |
| ZIP/Postal code |
02215 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
| Samples (12)
|
|
| This SubSeries is part of SuperSeries: |
| GSE186899 |
MKL-1 Merkel cell carcinoma cells treated with EPZ011989 |
|
| Relations |
| BioProject |
PRJNA776722 |
| SRA |
SRP343993 |
Less...
More...